MOTS-c

MOTS-c (mitochondrial-derived peptide) is currently being investigated for several metabolic and inflammatory conditions, though clinical evidence remains limited and primarily from preclinical studies.

Current Clinical Investigation Areas

Metabolic Disorders
One active Phase 2 clinical trial is recruiting participants to evaluate MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity (NCT07505745). This represents the most advanced clinical testing of MOTS-c as a therapeutic intervention.

Cardiovascular Disease
A clinical study is examining MOTS-c levels alongside other biomarkers in type 2 diabetics with coronary artery disease, investigating potential associations with platelet reactivity and mortality outcomes (NCT04027712). However, the current status of this trial is unknown.

Surgical Applications
Researchers are investigating how different anesthesia approaches during renal transplantation affect MOTS-c levels, examining its relationship with cellular stress pathways (NCT07678073).

Preclinical Evidence for Potential Applications

Recent preclinical research suggests MOTS-c may have therapeutic potential in several areas:

Metabolic and Inflammatory Conditions

• Studies indicate MOTS-c may suppress inflammatory responses in diabetic models and reduce cardiac inflammation
• Research suggests reduced MOTS-c levels in autoimmune thyroid conditions (Hashimoto's thyroiditis), potentially reflecting metabolic dysfunction

Cardiovascular Applications

• Preclinical evidence suggests MOTS-c may protect against heart damage during ischemia-reperfusion injury and help prevent atrial fibrillation through anti-fibrotic mechanisms

Muscle Wasting

• Early research indicates MOTS-c may provide partial protection against muscle deterioration in cancer cachexia models

Respiratory Conditions

• Preliminary studies suggest potential applications for inflammatory lung diseases, though specific mechanisms require further investigation

Clinical Evidence Limitations

The clinical evidence for MOTS-c remains very limited. Most findings come from preclinical studies in animal models or observational research measuring MOTS-c levels in various disease states. Only one Phase 2 trial is actively testing MOTS-c as a therapeutic intervention. More robust clinical trials are needed to establish safety, efficacy, and optimal dosing for any potential therapeutic applications.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for personalized medical guidance.